WO2006021814A3 - Medicament - Google Patents
Medicament Download PDFInfo
- Publication number
- WO2006021814A3 WO2006021814A3 PCT/GB2005/050108 GB2005050108W WO2006021814A3 WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3 GB 2005050108 W GB2005050108 W GB 2005050108W WO 2006021814 A3 WO2006021814 A3 WO 2006021814A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptides
- well
- product
- products
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
Abstract
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ552412A NZ552412A (en) | 2004-07-08 | 2005-07-08 | Use of corticotropin releasing factor in the treatment of neural disorders |
AU2005276242A AU2005276242B2 (en) | 2004-07-08 | 2005-07-08 | Medicament |
BRPI0513062-0A BRPI0513062A (en) | 2004-07-08 | 2005-07-08 | pharmaceutical composition, method of stimulating pomc production in a patient, uses of an isolated crf peptide and an isolated pomc peptide, and methods of treating a disease, producing crf and curative, enhancer or prophylactic treatment of a disease |
EP05758978A EP1765377A2 (en) | 2004-07-08 | 2005-07-08 | Medicament |
CA002572777A CA2572777A1 (en) | 2004-07-08 | 2005-07-08 | Medicament comprising corticotropin releasing factor and proopiomelanocortin, and uses thereof |
MX2007000144A MX2007000144A (en) | 2004-07-08 | 2005-07-08 | Medicament. |
EA200700115A EA011389B1 (en) | 2004-07-08 | 2005-07-08 | Medicament |
US11/631,067 US20080207500A1 (en) | 2004-07-08 | 2005-07-08 | Medicament |
KR1020077002992A KR101235723B1 (en) | 2004-07-08 | 2005-07-08 | Medicament |
JP2007519893A JP2008505878A (en) | 2004-07-08 | 2005-07-08 | Medicine |
IL180487A IL180487A (en) | 2004-07-08 | 2007-01-01 | Corticotropin releasing factor (crf) for treatment of neural disorders |
US13/544,413 US20130203669A1 (en) | 2004-07-08 | 2012-07-09 | Medicament |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0415359.9 | 2004-07-08 | ||
GBGB0415359.9A GB0415359D0 (en) | 2004-07-08 | 2004-07-08 | Medicament |
GB0423386.2 | 2004-10-21 | ||
GBGB0423386.2A GB0423386D0 (en) | 2004-07-08 | 2004-10-21 | Medicament |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US63103708A Continuation | 2004-07-08 | 2008-01-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006021814A2 WO2006021814A2 (en) | 2006-03-02 |
WO2006021814A3 true WO2006021814A3 (en) | 2007-03-29 |
Family
ID=35967903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2005/050108 WO2006021814A2 (en) | 2004-07-08 | 2005-07-08 | Medicament |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1765377A2 (en) |
JP (1) | JP2008505878A (en) |
KR (1) | KR101235723B1 (en) |
AU (1) | AU2005276242B2 (en) |
BR (1) | BRPI0513062A (en) |
CA (1) | CA2572777A1 (en) |
WO (1) | WO2006021814A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0415359D0 (en) * | 2004-07-08 | 2004-08-11 | Aimsco Ltd | Medicament |
GB0509052D0 (en) * | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
GB0600202D0 (en) * | 2006-01-06 | 2006-02-15 | Aimsco Ltd | Treatment of HIV |
WO2008049011A2 (en) | 2006-10-18 | 2008-04-24 | Research Development Foundation | Alpha-msh therapies for treatment of autoimmune disease |
KR20100056523A (en) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | Use of grf-1 (1-29) and corticotropin-releasing factor as therapeutic agents |
EP2197465A2 (en) * | 2007-09-11 | 2010-06-23 | Mondobiotech Laboratories AG | Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
JP5395794B2 (en) * | 2007-09-11 | 2014-01-22 | モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト | Use of galanin peptides as therapeutic agents |
NZ588877A (en) * | 2008-04-30 | 2012-08-31 | Neutron Row | Methods of using corticotropin-releasing factor for the treatment of cancer |
US20100203048A1 (en) | 2008-04-30 | 2010-08-12 | Stephen Evans-Freke | Methods of using corticotropin-releasing factor for the use of the treatment of cancer |
GB0910032D0 (en) * | 2009-06-11 | 2009-07-22 | Aimsco Ltd | Use of serum composition to reduce the levels of TNF and/or VEGF in mammals |
US20130259875A1 (en) * | 2010-05-11 | 2013-10-03 | Questcor Pharmaceuticals, Inc. | Acth for treatment of amyotrophic lateral sclerosis |
EP2701728B1 (en) * | 2012-06-25 | 2015-05-06 | Aimsco Limited | Formulation comprising crh and alpha-2-macroglobulin |
WO2015033175A1 (en) * | 2013-09-06 | 2015-03-12 | Zlatko Ademovic | Combination of pro-opiomelanocortin endogenous peptides in autoimmune disease treatment |
GB201322948D0 (en) * | 2013-12-23 | 2014-02-12 | Aimsco Ltd | Improved formulation |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
CN116970607A (en) | 2014-03-19 | 2023-10-31 | Ionis制药公司 | Compositions for modulating ataxin 2 expression |
GB201617175D0 (en) | 2016-10-10 | 2016-11-23 | Iconic Intellectual Property Limited | Assay |
KR20210038589A (en) | 2018-07-25 | 2021-04-07 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for reducing ATXN2 expression |
GB201911063D0 (en) | 2019-08-02 | 2019-09-18 | Tarian Biologics Ltd | Formulations |
GB201911064D0 (en) | 2019-08-02 | 2019-09-18 | Tarian Biologics Ltd | Therapy |
KR102551880B1 (en) * | 2020-11-13 | 2023-07-05 | 성균관대학교산학협력단 | Composition for promoting the formation of neurosphere comprising Corticotropin-releasing hormone as an active ingredient |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US5306710A (en) * | 1989-07-28 | 1994-04-26 | Regents Of The University Of California | Method for treating endotoxin shock with CRF |
WO1995023214A1 (en) * | 1994-02-28 | 1995-08-31 | Ludwig Institute For Cancer Research | Method for stimulating profileration of colon cells using pomc¿76-103? |
WO2002067996A2 (en) * | 2001-02-24 | 2002-09-06 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Beta-endorphin/crf gene therapy for locally combating pain |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4407489A1 (en) * | 1994-03-07 | 1995-09-14 | Bayer Ag | Vaccine for the prevention of respiratory and reproductive diseases of the pig |
US20030186867A1 (en) * | 2000-03-31 | 2003-10-02 | Laura Facci | Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
US20100291102A1 (en) * | 2001-07-02 | 2010-11-18 | Ice Biologics Limited | Therapeutic Agent |
AU2003202093B2 (en) * | 2001-07-02 | 2010-05-13 | Aimsco Limited | Treatment of MS with goat serum |
-
2005
- 2005-07-08 EP EP05758978A patent/EP1765377A2/en not_active Withdrawn
- 2005-07-08 JP JP2007519893A patent/JP2008505878A/en not_active Withdrawn
- 2005-07-08 BR BRPI0513062-0A patent/BRPI0513062A/en not_active IP Right Cessation
- 2005-07-08 WO PCT/GB2005/050108 patent/WO2006021814A2/en active Application Filing
- 2005-07-08 KR KR1020077002992A patent/KR101235723B1/en not_active IP Right Cessation
- 2005-07-08 CA CA002572777A patent/CA2572777A1/en not_active Abandoned
- 2005-07-08 AU AU2005276242A patent/AU2005276242B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
US5306710A (en) * | 1989-07-28 | 1994-04-26 | Regents Of The University Of California | Method for treating endotoxin shock with CRF |
WO1995023214A1 (en) * | 1994-02-28 | 1995-08-31 | Ludwig Institute For Cancer Research | Method for stimulating profileration of colon cells using pomc¿76-103? |
WO2002067996A2 (en) * | 2001-02-24 | 2002-09-06 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Beta-endorphin/crf gene therapy for locally combating pain |
Also Published As
Publication number | Publication date |
---|---|
WO2006021814A2 (en) | 2006-03-02 |
BRPI0513062A (en) | 2008-04-22 |
AU2005276242A1 (en) | 2006-03-02 |
KR101235723B1 (en) | 2013-02-21 |
AU2005276242B2 (en) | 2011-08-25 |
EP1765377A2 (en) | 2007-03-28 |
KR20070042546A (en) | 2007-04-23 |
JP2008505878A (en) | 2008-02-28 |
CA2572777A1 (en) | 2006-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006021814A3 (en) | Medicament | |
WO2004065423A3 (en) | Recognition molecules for the treatment and detection of tumours | |
WO2005102287A3 (en) | Pharmaceutical compositions for acute glucocorticoid therapy | |
WO2006048449A3 (en) | Mc4r selective peptides and their use in the treatment of obesity | |
WO2007009894A3 (en) | Peptides for use in the treatment of obesity | |
WO2005078124A3 (en) | Diagnostic marker for cancer | |
WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
WO2006048450A3 (en) | Peptides for use in the treating obesity | |
IL172613A (en) | Antibodies that bind at least two different human inhibitory kir gene products, hybridomas producing said antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies and use thereof for the manufacture of a medicament to potentiate nk cell activity | |
WO2005014525A3 (en) | Bi-aryl compound having immunosuppressive activity | |
WO2006048452A3 (en) | Peptides for use in treating of obesity | |
WO2005103002A3 (en) | Novel alkyne compounds with an mch-antagonistic action and medicaments comprising said compounds | |
WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
WO2004071382A3 (en) | Substituted heterocycles | |
DE10337184A1 (en) | Substituted 3-pyrrolidine-indole derivatives | |
WO2006018632A3 (en) | Cell therapy with exo 1 | |
WO2020057540A8 (en) | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer | |
WO2012116229A3 (en) | Compositions and methods for personal tumor profiling treatment | |
WO2005083083A3 (en) | Materials and methods for treatment of allergic disease | |
Lee et al. | Effects of magnolialide isolated from the leaves of Laurus nobilis L.(Lauraceae) on immunoglobulin E-mediated type I hypersensitivity in vitro | |
GB0415359D0 (en) | Medicament | |
EP1544214A4 (en) | Non-neutralizing anti-apc antibodies | |
DE602005004026D1 (en) | A transcription factor coding for humanism and its uses | |
TW200510437A (en) | Phosphinane compound with immunomodulating activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005276242 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 180487 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2572777 Country of ref document: CA Ref document number: 552412 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007519893 Country of ref document: JP Ref document number: 12007500061 Country of ref document: PH Ref document number: 2007/00286 Country of ref document: ZA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005758978 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 598/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700115 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2005276242 Country of ref document: AU Date of ref document: 20050708 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005276242 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077002992 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580028451.5 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005758978 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11631067 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0513062 Country of ref document: BR |